Itepekimab clinical trials
Itepekimab is named as an intervention in 3 current clinical trials in our UK, USA, Poland, Canada, China, Germany, Spain, Italy, Netherlands, Czechia, Turkey, Brazil, Mexico, Japan, Australia, Israel, Austria, Portugal, South Korea, France, Belgium, Denmark and Sweden registers. None are recruiting at the moment. All registered phases are Phase 3. The lead sponsor is Sanofi. The most-studied condition is Chronic Rhinosinusitis With Nasal Polyps. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Itepekimab works
All drug targets →- Interleukin-33 inhibitor InhibitorTarget: IL33 interleukin 33ChEMBL only
- Chronic obstructive pulmonary diseasePhase 3
- Chronic rhinosinusitis with nasal polypsPhase 3
- AsthmaPhase 2
- Atopic eczemaPhase 2
- BronchiectasisPhase 2
- Chronic rhinosinusitis without nasal polypsPhase 2
- Allergic asthmaPhase 1
- InflammationPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4594594, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Itepekimab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Itepekimab
3 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Itepekimab in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Itepekimab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies
2025-522983-33-00 · CTIS ↗ · Respiratory Tract Diseases
|
Phase 3 | Ongoing | Sanofi-Aventis Recherche & Developpement | Germany, Netherlands, Portugal + 12 more |
Conditions studied with Itepekimab
1 conditionSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Sanofi | 3 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Itepekimab trials
How many clinical trials are testing Itepekimab?
3 current trials in our UK, USA, Poland, Canada, China, Germany, Spain, Italy, Netherlands, Czechia, Turkey, Brazil, Mexico, Japan, Australia, Israel, Austria, Portugal, South Korea, France, Belgium, Denmark and Sweden registers name Itepekimab (also registered as SAR440340) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Itepekimab trials recruiting patients?
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors Itepekimab clinical trials?
The lead sponsor is Sanofi. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Itepekimab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Itepekimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Itepekimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.